AndhraNews.net
Home » Business News » 2013 » April » April 26, 2013

MorphoSys to Host Q1 2013 Conference Call on May 3, 2013


April 26, 2013 - Martinsried, Germany And Munchen, Germany

MorphoSys AG / MorphoSys to Host Q1 2013 Conference Call on May 3, 2013.

Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish itsfirstthree months' 2013 results on May 3, 2013 at 7:00 am CEST.At 2:00 pm CEST (1:00 pm BST, 8:00 am EDT), the Management Board ofMorphoSys AGwill host a public conference call and webcast to present MorphoSys'sfinancialresults for the first three months of 2013 and provide further details ontheCompany's latest developments.

Dial-in numbers (listen only):

Germany: +49 89 2444 32975

United Kingdom: +44 20 3003 2666

USA: +1 202 204 1514

An audio replay and manuscripts of the conference will be available onwww.morphosys.com/conference-calls in due course.

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technologyinthe pharmaceutical industry. By successfully applying this and otherpatentedtechnologies, MorphoSys has become a leader in the field of therapeuticantibodies, one of the fastest-growing drug classes in human healthcare.Together with its pharmaceutical partners, MorphoSys has built atherapeuticpipeline of more than 70 human antibody drug candidates for the treatmentofcancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.Withits ongoing commitment to new antibody technology and drug development,MorphoSys is focused on making the healthcare products of tomorrow.MorphoSys islisted on the Frankfurt Stock Exchange under the symbol MOR. For regularupdatesabout MorphoSys, visit http://www.morphosys.com.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,RapMAT®, arYla®, Ylanthia®and 100 billion high potentials® are registered trademarks ofMorphoSys AG.Slonomics® is a registered trademark of Sloning BioTechnology GmbH, asubsidiaryof MorphoSys AG.

This communication contains certain forward-looking statements concerningtheMorphoSys group of companies. The forward-looking statements containedhereinrepresent the judgment of MorphoSys as of the date of this release andinvolverisks and uncertainties. Should actual conditions differ from the Company'sassumptions, actual results and actions may differ from those anticipated.MorphoSys does not intend to update any of theseforward-looking statements asfar as the wording of the relevant press release is concerned.

investors@morphosys.com

Media Release (PDF):

http://hugin.info/130295/R/1696842/558995.pdf

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

[HUG#1696842]

For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Loser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

MarketWire

Comment on this story

Share